Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and... see more

TSXV:THRM - Post Discussion

Therma Bright Inc > INTERESTING
View:
Post by 13X2413 on Apr 07, 2022 1:03pm

INTERESTING

 

In February, the Ontario COVID-19 Science Advisory Table published findings from an analysis of preprint studies suggesting that the pooled sensitivity of rapid antigen tests for detecting Omicron infections is about 37 per cent, compared to 81 per cent for the Delta variant.

Health Canada says on its website that it has "no evidence" that variants affect the ability of agency-approved tests to confirm COVID-19 cases, but notes that these new devices are still being investigated.

Comment by Smokey1958 on Apr 07, 2022 1:20pm
If you read a little more about this you will find that the reason behind these findings is exactly why AcuVid could and should be a gamechanger. The issue is one of sample type and location of predominant infection. Omicron most typically infects the upper respiratory tract while delta was deeper in the lungs. As such nasal swabs were least effective in detecting omicron and the recommendation ...more  
Comment by 13X2413 on Apr 07, 2022 1:25pm
Holding out hope the the new devices being investigated are THRM's and the investigation comes up smelling roses. 
Comment by TomConstantine on Apr 07, 2022 3:32pm
https://youtu.be/aIFOpEGcgKo
Comment by nrv090909 on Apr 07, 2022 3:36pm
Hurry up FDA, what is taking so long, you know what you want... the suspense is hard in waiting. GLTA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities